阿帕替尼治疗多线治疗失败晚期乳腺癌的近期疗效观察

Recent Clinical Observation of Apatinib in Patients with Heavily Pretreated Metastatic Breast Cancer

目的观察甲磺酸阿帕替尼单药治疗多线治疗失败的晚期乳腺癌的有效性及安全性。方法 26例患者接受甲磺酸阿帕替尼治疗,500 mg/d,口服,若出现严重不可耐受的不良反应,改为250 mg/d,并维持治疗,通过影像学检查评价近期疗效。结果 26例接受甲磺酸阿帕替尼靶向治疗的晚期乳腺癌患者中,完全缓解(CR)0例,部分缓解(PR)5例,稳定(SD)14例,进展(PD)7例,总有效率为19.2%(5/26),疾病控制率73.1%(19/26)。且乳腺癌不同转移部位对预后无影响(P均>0.05)。不良反应主要是高血压及蛋白尿,发生率分别为65.4%和46.2%。结论甲磺酸阿帕替尼治疗多线治疗失败的晚期乳腺癌近期疗效较好,不良反应可以耐受及控制,可在临床使用并进一步研究其长期疗效及远期不良反应。

Objective To evaluate the efficacy and safety of apatinib in patients with heavily pretreated metastatic breast cancer. Method Twenty-six patients received treatment of apatinib at a dose of 500 mg/day, then at a dose of 250 mg/day if could not be tolerated. The efficacy was evaluated by the imaging. Results The clinical evaluation of patients were complete remission（CR） 0 case, partial remission（PR） 5 cases, steady（SD） 14 cases, progress（PD） 7 cases, and the objective response rate was 19.2%（5/26）, disease control rate was 73.1（19/26）. The impacts on prognosis of different metastatic sites were no statistical significant difference（P0.05）. The main side effects were hypertension and proteinuria（65.4% and 46.2%）. Conclusion The treatment of chemotherapy-failed advanced breast cancer with apatinib has better exact effect, and toxicity could be controlled, so it worthy of clinical treatment and evaluation of long-term efficacy.